Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma

UNC Libraries(2020)10.17615/qcvm-v108Source: DataRank Database

mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma is a research paper published in UNC Libraries (2020). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.00)OA: greenTopics (38)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Harper L. Wilson ORCID,Jeffrey S. Damrauer ORCID,Aleisha M. Smith,Jen Jen Yeh ORCID,William Y. Kim ORCID

Live enrichment

PubMed:21097893 OpenAlex:https://openalex.org/W4302591003

National Institutes of Health

Grant: 5F31CA159897-02

Discovery of Molecular and Imaging Biomarkers in RCC patient-Derived Tumorgrafts

National Institutes of Health

Grant: 5R01CA142794-04

Characterization and therapeutic targeting of HIF in LKB1 - deficient lung cancer

National Institutes of Health

Grant: 5T32HL069768-19

Pre-doctoral Training Program in Integrative Vascular Biology

National Institutes of Health

Grant: 5T32GM007092-28

NRSA IN GENETICS

FWCI

0.00

Citation Percentile

0.4%

greenLicense: CC BY

repositoryhttps://doi.org/10.17615/qcvm-v108

https://doi.org/10.1371/journal.pone.0104413

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0104413&type=printable

https://dx.doi.org/10.17615/qcvm-v108

https://pubmed.ncbi.nlm.nih.gov/25180793

Fields of Study

Renal cell carcinoma treatmentBiological Research and Disease Studies0301 basic medicine03 medical and health sciences0303 health sciences

Keywords

PI3K/AKT/mTOR pathwayRenal cell carcinomaCancer researchDiscovery and development of mTOR inhibitorsMedicineInternal medicineBiologyCell biologySignal transductionScienceApoptosisMechanistic Target of Rapamycin Complex 2Mechanistic Target of Rapamycin Complex 1MiceAllosteric RegulationCell Line, TumorAnimalsHumansMolecular Targeted TherapyPhosphorylationExtracellular Signal-Regulated MAP KinasesCarcinoma, Renal CellProtein Kinase InhibitorsCell ProliferationMitogen-Activated Protein Kinase KinasesQRHypoxia-Inducible Factor 1, alpha SubunitKidney NeoplasmsEnzyme ActivationMultiprotein ComplexesBiocatalysisResearch Article

Sustainable Development Goals

SDG 3: 3. Good health